CTC
PTCT icon

Central Trust Company’s PTC Therapeutics PTCT Stock Holding History

Central Trust Company’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43
Closed -$2.1K – 1494
2025
Q2 		$2.1K Hold
43
– – ﹤0.01% 1314
2025
Q1 		$2.19K Hold
43
– – ﹤0.01% 1304
2024
Q4 		$1.94K Hold
43
– – ﹤0.01% 1326
2024
Q3 		$1.6K Hold
43
– – ﹤0.01% 1278
2024
Q2 		$1.31K Hold
43
– – ﹤0.01% 1316
2024
Q1 		$1.25K Hold
43
– – ﹤0.01% 1307
2023
Q4 		$1.19K Hold
43
– – ﹤0.01% 1320
2023
Q3 		$964 Buy
+43
New +$1.6K ﹤0.01% 1312

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Central Trust Company's PTCT Position: Q3 2025 in Review

Central Trust Company sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 43 shares — an estimated $2.1K sold.

Central Trust Company first reported a position in PTCT in Q3 2023 and held it in 8 quarters. The position peaked at $2.19K in Q1 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Central Trust Company reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 43 PTC Therapeutics shares in Q3 2025, an estimated $2.1K.
  • Central Trust Company first reported a position in PTC Therapeutics in Q3 2023 and held it in 8 quarters.
  • Central Trust Company's PTC Therapeutics position peaked at $2.19K in Q1 2025.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.